Register for OBR daily


Kantar Health Conference Sidebar

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

EXEL $4.21 0.4300 +11.38%
AGEN $3.39 0.3400 +11.15%
CBMG $21.57 1.5100 +7.53%
CLSN $3.40 0.1700 +5.26%
ARIA $6.18 0.3030 +5.15%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

PBYI $212.92 -20.5100 -8.79%
ONTY $3.06 -0.2300 -6.99%
MNKD $9.00 -0.5600 -5.86%
DRNA $14.90 -0.8800 -5.58%
SCLN $5.06 -0.2600 -4.89%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 888 | 889 | 890 | 891 | 892 | 893 | 894 | 895 | 896 | 897 | Next > | Last >>

High CTC Levels Predicted Poor Outcome in Metastatic Breast Cancer

(AACR) Dec 10, 2010 - A high level of circulating tumor cells (CTCs) — cells that have detached from a tumor and are circulating in the body through the blood — are an independent prognostic marker in metastatic breast cancer as first-line therapy.
read press release 



Neoprobe, FDA Work to Map Plan for Cancer-Targeting Agent

(MedCity News, Cleveland) Dec 9, 2010 - Neoprobe Corp. continues to take steps down the regulatory path aimed at restarting development efforts for its RIGScan cancer-detecting technology.
read article 



Poor Breast Cancer Prognosis Associated With Presence of Circulating Tumor, Cancer Stem Cells

(MD Anderson) Dec 10, 2010 - Metastatic breast cancer patients whose blood contains circulating tumor cells (CTCs) before or after treatment with high-dose chemotherapy and blood stem cell transplant have shorter survival periods, according to a new study by researchers at The University of Texas MD Anderson Cancer Center in Houston.
read press release 



Eisai Marks Fully-Fledged Entry into Japanese Oncology Market with Launch of Anticancer Agent Treakisym(R) Injection 100 MG

(EuroInvestor.com) Dec 10, 2010 - Eisai Co., Ltd. today launched the anticancer agent TREAKISYM(R) Injection 100 mg (bendamustine hydrochloride) in Japan as a treatment for low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma.
read article 



Fox Chase Researchers Uncover New Risk Factors for Brain Metastases in Breast Cancer Patients

(FCCC) Dec 9, 2010 - Nearly one-fifth of all metastatic breast cancer patients develop brain metastases and have significantly shorter overall survival than patients who do not have brain involvement. One way to improve the affected patients’ survival might be to prevent the brain metastases from arising in the first place.
read press release 



Neogenix Oncology® to Collaborate with IRCCS San Raffaele Pisana on Cancer Diagnostic Research

(Yahoo! Finance) Dec 9, 201 - Neogenix Oncology, Inc. announced today that it is entering a research collaboration with IRCCS San Raffaele Pisana in Rome, Italy led by Dr. Fiorella Guadagni.
read article 



AVEO’s Tivozanib in Combination with Paclitaxel Demonstrates Safety in Patients with Metastatic Breast Cancer; Data Presented at San Antonio Breast Cancer Symposium

(TheStreet) Dec 10, 2010 - AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preliminary results from an ongoing Phase 1b clinical trial evaluating the company’s lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol®), a standard chemotherapy regimen, in patients with metastatic breast cancer.
read article 



George Sledge Jr. Honored for International Contributions to Breast Cancer Research

(Indiana University) Dec 10, 2010 - George W. Sledge Jr., a nationally recognized pioneer in the development of novel therapies for breast cancer, will receive the 2010 William L. McGuire Memorial Lecture Award at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
read press release 



EpiCept Reports New Analysis Supports Ceplene's Favorable Impact on Overall Survival

(EpiCept) Dec 10, 2010 - EpiCept Corporation today announced the results of a new analysis supporting Ceplene's (histamine dihydrochloride) favorable impact on overall survival and its activity with interleukin-2 (IL-2). Ceplene® is approved in the European Union for the maintenance of first remission in patients with Acute Myeloid Leukemia (AML) in conjunction with low dose IL-2.
read press release 



Perou Chairs Panel Discussion at 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium

(UNC Lineberger CCC) Dec 10, 2010 - Charles M. Perou, PhD, Professor of Genetics and member of UNC Lineberger Comprehensive Cancer Center, chaired a panel at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium on the topic of “Next Generation Sequencing for the Clinician.”
read press release 



OncoVEX Phase III Trial for Head and Neck Cancers Commences

(ICR) Dec 9, 2010 - Biotechnology company BioVex Inc has announced the start of a Phase III study using the drug OncoVEX, a genetically engineered cold sore virus, to treat patients newly-diagnosed with locally advanced head and neck cancer.
read press release 



Baselga First Incumbent of Chabner Chair in Hematology Oncology

(MGH) Dec 10, 2010 - A named chair is one of the highest honors a physician may receive in his or her lifetime. On Nov. 19, the MGH, the MGH Cancer Center and the Department of Medicine celebrated the establishment of the Bruce A. Chabner Chair in Hematology Oncology, named in honor of Bruce A. Chabner, MD, director of Clinical Research for the Cancer Center.
read press release 



'Natural Killers' Unleashed to Search and Destroy Cancer

(Miami Herald) Dec 9, 2010 - Doctors at the University of Miami are treating liver cancer patients by giving immune-system cells more muscle in the lab to recognize and attack their cancer cells.
read article 



Molecular Insight Seeks Bankruptcy After Bondholders Reject Restructuring

(Bloomberg) Dec 10, 2010 - Molecular Insight Pharmaceuticals Inc., a developer of therapeutic and imaging radiopharmaceuticals for cancer treatment, filed for bankruptcy protection after bondholders rejected a restructuring plan.
read article 



Rare Genetic Syndrome May Increase Colon Cancer Risk

(U.S News & World Report) Dec 10, 2010 - Patients diagnosed with a genetic condition known as Cowden syndrome face an increased risk for colon cancer, new research suggests.
read article 



Broccoli May Not Fight Lung Cancer in Non-Smokers

(Reuters) Dec 10, 2010 - Some studies have hinted that eating your broccoli might help prevent lung cancer. But a new study of non-smoking women finds no strong link between compounds found in cruciferous vegetables such as broccoli and lower risk of lung cancer.
read article 



Drug Combo Helps Women With Early Breast Cancer

(New York Times/AP) Dec 10, 2010 - A new study finds that using two drugs, Herceptin (her-SEPT-in) and Tykerb (TIE-curb), more than doubles the number of women with early breast cancer whose tumors disappear before they are scheduled to have surgery to remove them.
read article (free registration required) 



Amgen Drug Delays Bone Problems Longer Than Zometa

(Reuters) Dec 10, 2010 - Amgen Inc's new osteoporosis drug denosumab delayed fractures and other bone problems in patients with advanced breast cancer five months longer than Novartis AG's Zometa, according to data from a large clinical trial.
read article 



Bone Drug Zometa Disappoints in Breast Cancer Study

(USA Today) Dec 10, 2010 - One of the most promising new approaches for fighting breast cancer took a stunning setback Thursday when a major study showed that a bone-building drug did not stop cancer from returning or extend life for most women fighting the disease.
read article 



Pfizer Recalls Lung Drug After Two Deaths

(Reuters) Dec 10, 2010 - Pfizer Inc is voluntarily recalling its drug to treat a life-threatening lung condition and will end studies of the pill after it was linked to potentially deadly liver toxicity.
read article 



Life Expectancy Drops Slightly, Bucking Established Trend

(New York Times) Dec 9, 2010 - Life expectancy in the United States has dropped slightly — by about a month — after inching up in most years, the government reported Thursday.
read article (free registration required) 



AMA, Physician Groups Urge CMS to Pay Overdue Reimbursements to Physicians

(AMA) Dec 10, 2010 - The American Medical Association (AMA), along with medical societies representing all 50 states and the District of Columbia and 57 national medical specialty societies, called on the Centers for Medicare and Medicaid Services (CMS) to use the $200 million allocated by Congress to provide physicians with long-overdue Medicare reimbursements for payments they should have received in 2010.
read press release 



Medicare Demonstrations Illustrate Benefits in Paying for Quality Healthcare

(CMS) Dec 9, 2010 - Results from three health care demonstrations announced today by the Centers for Medicare & Medicaid Services (CMS) provide strong evidence that offering providers financial incentives for improving patient care increases quality of care and can reduce the growth in Medicare expenditures.
read press release 



FDA Issues Guidance on Public Comment Procedures at Advisory Committee Meetings

(FDA) Dec 9, 2010 - The U.S. Food and Drug Administration today issued final guidance for people who wish to comment during the agency’s advisory committee meetings. The guidance provides instructions on how to request a time to speak and how FDA staff should respond to requests to speak at the meetings.
read press release 



Zoledronic Acid Did Not Improve Disease-Free Survival in Early Breast Cancer

(AACR) Dec 9, 2010 - Zoledronic acid did not improve disease-free survival among women with stage II/III breast cancer according to results of the Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer (AZURE) trial, which was presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
read press release